No votes yet


Treatment of Myelodysplastic Syndromes

Sandra E. Kurtin
Erin P. Demakos
Janet Hayden
Claudia Boglione
CJON 2012, 16(3), 23-35 DOI: 10.1188/12.CJON.S1.23-35

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid malignancies with variability in clinical presentation, disease trajectory, treatment goals, and expected outcomes. The treatment of patients with MDS, therefore, often differs from patient to patient. Tools are needed to aid effective communication with patients, their caregivers, and their dedicated team of healthcare professionals. The use of methods often employed in clinical trials can help healthcare providers diagnose and classify risk status, track trends within patient responses, manage adverse events, set treatment expectations, and provide ongoing supportive care. This article discusses several tools and strategies available for the management of patients with MDS throughout the continuum of their disease.